-
1
المؤلفون: Xue Du, Yanhong Tai, Yi Ban, Han Zhang, Hai-Feng Qin, Hongjun Gao, Yun Shao, Xueli Zhang
المصدر: Cancer Biology & Therapy
مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Methyltransferase, medicine.drug_class, Drug resistance, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase (ALK), ALK Rearrangement, Pharmacology, ALK-rearranged NSCLC, crizotinib, Bedside to Bench Report, CMTR1, Crizotinib, business.industry, fusion partner gene, ALK inhibitor, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Personalized oncology, Cancer research, Molecular Medicine, ALK-tyrosine kinase inhibitor (TKI), Non small cell, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025d44a46fb81315a4fc49205cffb266Test
https://doi.org/10.1080/15384047.2018.1480282Test -
2
المؤلفون: Annapaola Mariniello, Silvia Novello, Tiziana Vavalà
المصدر: Translational Cancer Research
مصطلحات موضوعية: ALK inhibitors, Cancer Research, medicine.drug_class, Non-small cell lung cancer (NSCLC), Review Article, medicine.disease_cause, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Radiology, Nuclear Medicine and imaging, Lung cancer, Mutation, Crizotinib, business.industry, medicine.disease, Reverse transcriptase, respiratory tract diseases, ALK inhibitor, anaplastic lymphoma kinase (ALK), Oncology, ALK tyrosine kinase inhibitor (ALK-TKI), Cancer research, Signal transduction, business, Tyrosine kinase, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d8f439a48f1f1b6d9bed768e47e2d8Test
http://hdl.handle.net/2318/1687660Test